Connect With the Companies Defining the Future of In Vivo CAR-T
The 5th In Vivo Cell Engineering & Gene Editing Summit has rapidly evolved into a focal meeting point for in vivo CAR-T innovation. With the space accelerating from preclinical promise to clinical validation, this summit positions your organization directly in front of decision-makers driving next-generation in vivo CAR-Ts and gene therapies.
Momentum in the field was underscored recently by Eli Lilly’s landmark partnership with Kelonia Therapeutics, the largest in vivo CAR-T deal to date, signaling strong pharma commitment to scalable, in vivo approaches to cell therapy.
Partnering this year signals that your services, expertise, and capabilities align with where the field is heading next and ensures your brand is front‑of‑mind as developers prepare the next wave of in vivo programs.
In Vivo CAR-T: The Deal-Making Hotspot in Cell Therapy
Across 2025 and 2026, the in vivo CAR-T landscape has seen accelerating deal activity, reflecting strong commercial validation from biopharma and investment communities.
Key highlighted transactions include:
- Eli Lilly & Kelonia Therapeutics (2026) – Largest in vivo CAR-T deal to date
- AbbVie & Capstan Therapeutics (2025) – Strategic acquisition strengthening in vivo CAR-T pipelines
- Transactions involving Kite Pharma, Bristol Myers Squibb, and AstraZeneca are reinforcing competitive urgency
This surge in deal-making is driving demand for delivery technologies, CDMO scale-up, and translational expertise across the in vivo CAR-T ecosystem.
What to Expect as a Partner?
Meet High‑Intent Prospects
Engage face‑to‑face with R&D, translational, CMC, and business development leaders seeking partners for manufacturing, delivery optimization, analytical development, safety testing, and IND‑enabling support.
Strengthen Your Position in a Competitive Market
Place your brand directly in front of companies preparing the next wave of editing, delivery, and early clinical programs, ensuring your organization is seen as ready to support this shift.
Demonstrate Your Expertise
Showcase your capabilities through speaking opportunities, panel participation, or a tailored exhibition presence designed to highlight your unique strengths in supporting in vivo development.
Gain Real‑Time Market Intelligence
Key Interest Areas
Our attendees are actively seeking partners with capabilities across the in vivo development ecosystem, including but not limited to the areas below.
Non-Viral Vector CDMOs & Technology Providers
Acrpss lipid nanoparticles (LNPs), novel delivery systems, targeting and cell-specific uptake solutions enabling in vivo CAR-T
Viral Vector CDMOs & Technology Providers
Specializing in optimized AAV and lentiviral platforms supporting in vivo gene delivery
Global CRO Organizations
From preclinical through early clinical support for in vivo CAR-T pipelines
Preclinical Model Providers
Across relevant disease and immune models, validating in vivo CAR-T efficacy and safety
Other Solutions for In Vivo Drug Developers
Including analytics, CMC, regulatory, and enabling technologies
Position Yourself at the Center of In Vivo CAR-T Progress
As in vivo CAR-T transitions from an experimental concept to an investable modality, we can position your organization at this summit to demonstrate leadership and relevance in one of the most competitive areas of precision medicine. Align your brand with the companies shaping the next wave of immuno-oncology and autoimmune therapeutics.
Audience Composition
Company Type
Attendee Seniority
Attending Companies Include
Available Inventory
We offer a range of partnership opportunities designed to elevate your visibility, demonstrate your expertise, and position your organization as a critical partner in the fast-growing in vivo cell engineering and gene editing space.
Get in Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
Jake Bennett
Partnerships Director